Table 2.
Baseline medication use
| Baseline medication use | n = 9444 |
|---|---|
| Anti-thrombotic, n (%) | 8876 (94.0%) |
| ȃAny antiplatelet | 1769 (18.7%) |
| ȃȃAcetylsalicylic acid | 1588 (16.8%) |
| ȃȃClopidogrel | 547 (5.8%) |
| ȃOral anticoagulants, n (%) | 8296 (87.9%) |
| ȃȃVitamin K antagonist | 4721 (50.0%) |
| ȃȃAny NOAC | 3429 (36.3%) |
| ȃȃȃApixaban | 956 (10.1%) |
| ȃȃȃDabigatran | 756 (8.0%) |
| ȃȃȃEdoxaban | 94 (1.0%) |
| ȃȃȃRivaroxaban | 1623 (17.2%) |
| ȃȃHeparin | 146 (1.5%) |
| Anti-arrhythmics, n (%) | 2610 (27.7%) |
| ȃAmiodarone | 1638 (17.4%) |
| ȃFlecainide | 341 (3.6%) |
| ȃPropafenone | 325 (3.5%) |
| ȃSotalol | 275 (2.9%) |
| Other medications, n (%) | |
| ȃACE inhibitors | 3944 (41.9%) |
| ȃAldosterone blockers | 1673 (17.8%) |
| ȃAngiotensin receptor blocker | 1843 (19.6%) |
| ȃBeta-blockers | 6529 (69.4%) |
| ȃDihydropyridine CCB | 1617 (17.2%) |
| ȃDigoxin | 1321 (14.0%) |
| ȃDiuretics | 4761 (50.6%) |
| ȃInsulin | 510 (5.4%) |
| ȃOral antidiabetics | 1425 (15.1%) |
| ȃStatins | 3999 (42.5%) |
ACE, angiotensin converting enzyme; CCB, calcium-channel blocker; eGFR, estimated glomerular filtration rate; NOAC, non-vitamin K antagonist oral anticoagulant.